Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antithrombogenic elastomers: novel anticoagulant/complement inhibitor-controlled release systems.

T Matsuda, H Iwata, H Noda

    Transactions - American Society for Artificial Internal Organs
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Evidence for the covalent binding of SHAP, heavy chains of inter-alpha-trypsin inhibitor, to hyaluronan.

    The Journal of biological chemistry·1995
    Same author

    [Clean intermittent catheterization in neurogenic bladder patients with vesicoureteral reflux].

    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology·1995
    Same author

    [A trial of antegrade perfusion to the lower half of the body with selective cerebral perfusion for repair of aortic arch aneurysm combined with atherosclerosis obliterance].

    Kyobu geka. The Japanese journal of thoracic surgery·1995
    Same author

    Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analogue of 1 alpha, 25-dihydroxyvitamin D3.

    Carcinogenesis·1995
    Same author

    Varus derotation osteotomy for persistent dysplasia in congenital dislocation of the hip. Proximal femoral growth and alignment changes in the leg.

    The Journal of bone and joint surgery. British volume·1995
    Same author

    Effects of chondroitinase ABC on degenerative intervertebral discs.

    Clinical orthopaedics and related research·1995

    Novel synthetic drugs were developed for controlled release systems, offering high biocompatibility and tunable drug release rates. These anticoagulant and complement inhibitors are designed for versatile applications in hydrophilic polymers.

    Area of Science:

    • Biomaterials Science
    • Drug Delivery Systems
    • Pharmacology

    Background:

    • Controlled release systems are crucial for therapeutic efficacy and patient compliance.
    • Developing biocompatible materials with tunable drug release profiles remains a significant challenge.
    • Synthetic anticoagulants and complement inhibitors require advanced delivery mechanisms.

    Purpose of the Study:

    • To introduce novel synthetic anticoagulant and complement inhibitors for controlled release.
    • To achieve high biocompatibility and biospecific inhibition.
    • To enable versatile applications in hydrophilic polymeric systems.

    Main Methods:

    • Molecular design of synthetic anticoagulant and complement inhibitors.
    • One-step co-casting technique for drug impregnation into hydrophilic polymers.

    Related Experiment Videos

  • Manipulation of material, formulation, and fabrication variables (e.g., polymer hydrophilicity, drug loading, film thickness) to control release kinetics.

    • Main Results:

    • The developed drugs exhibit high biospecific inhibition and solubility in polar organic solvents.
    • The controlled release system demonstrates high biocompatibility.
    • Drug release rate and duration are effectively controlled by material properties and fabrication parameters.
    • The system allows for versatile applications in commonly used hydrophilic polymeric systems.

    Conclusions:

    • Novel synthetic anticoagulant and complement inhibitors offer a promising platform for advanced controlled release systems.
    • The developed drug-impregnated systems provide tunable release profiles and high biocompatibility.
    • This approach represents a new dimension in the formulation of biocompatible controlled release drug delivery systems.